Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors significantly prolong the progression-free survival of patients with non-squamous non-small cell lung cancer (NSCLC). However, most patients develop tumor regrowth and their prognosis remains poor. A new treatment strategy for N...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Genes Cancer
Main Authors: Kurata, Takayasu, Nakaya, Aya, Yokoi, Takashi, Niki, Maiko, Kibata, Kayoko, Takeyasu, Yuki, Torii, Yoshitaro, Katashiba, Yuichi, Ogata, Makoto, Miyara, Takayuki, Nomura, Shosaku
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5511889/
https://ncbi.nlm.nih.gov/pubmed/28740574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/genesandcancer.145
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados